MHYOSPHERE®PCV ID: ESPHM Publications 2021

MHYOSPHERE® PCV ID is the first and only vaccine based on a recombinant Mycoplasma hyopneumoniae (M. hyo) strain, called Nexyhon. This strain expresses the capsid proteins of Porcine Circovirus Type 2 (PCV2) in its cytoplasm and acts as the only active substance as a whole once inactivated. Furthermore, it was the first vaccine registered in Europe with demonstrated protection against all three PCV2 genotypes (a, b and d).
calendar icon 13 July 2021
clock icon 9 minute read

Statistically significant differences were also detected in the culling rate just before slaughter with 5.2% fewer pigs weighting less than 75 kg at slaughter in the MHYOSPHERE® PCV ID group (p <0.001, X2 test).

Take home messages:

MHYOSPHERE® PCV ID proved to:

  1. Reduce pulmonary lesions associated with enzootic pneumonia of swine caused by Mycoplasma hyopneumoniae. Also reduce the incidence of these lesions (as observed in field studies).
  2. Reduce PCV2 viraemia and the duration thereof, and reduce the tissue viral load in the tonsils, lungs, and mesenteric lymph nodes.
  3. Provide cross-protection among different PCV2 genotypes (a, b and d), as also seen in field studies.
  4. Have direct implications for growth, showing a higher ADG between weaning and before slaughter, and a lower culling rate (<75 kg) at the end of fattening.
Figure 1. Percentage of lung surface area affected by M. hyo-like lesions.  *Different letters indicate statistically significant differences, p <0.05,  Welch’s test.
Figure 1. Percentage of lung surface area affected by M. hyo-like lesions. *Different letters indicate statistically significant differences, p <0.05, Welch’s test.
Figure 2. Viraemia due to PCV2 (qPCR). The area under the curve (AUC)  was lower in the vaccinated group (p <0.05, Mann–Whitney U test).
Figure 2. Viraemia due to PCV2 (qPCR). The area under the curve (AUC) was lower in the vaccinated group (p <0.05, Mann–Whitney U test).
Figure 3. Percentage of lung surface area affected by lesions consistent  with M. hyo. Different letters indicate statistically significant differences, p  <0.0001, Mann–Whitney U test.
Figure 3. Percentage of lung surface area affected by lesions consistent with M. hyo. Different letters indicate statistically significant differences, p <0.0001, Mann–Whitney U test.
Figure 4. Viraemia due to PCV2. The area under the curve (AUC) was lower in the vaccinated group (p <0.001, mixed linear model).
Figure 4. Viraemia due to PCV2. The area under the curve (AUC) was lower in the vaccinated group (p <0.001, mixed linear model).
Table 1. Area under the curve (AUC) of the group vaccinated with  MHYOSPHERE® PCV ID, and the control group, grouped by PCV2 genotype.  Different superscripts indicate statistically significant differences.
Table 1. Area under the curve (AUC) of the group vaccinated with MHYOSPHERE® PCV ID, and the control group, grouped by PCV2 genotype. Different superscripts indicate statistically significant differences.
Table 2. ADG ± standard error of measurement (SEM) during different  production periods. Units expressed in grams per day.
Table 2. ADG ± standard error of measurement (SEM) during different production periods. Units expressed in grams per day.
Figure 5. Mean body weight (± SEM) at the end of fattening
Figure 5. Mean body weight (± SEM) at the end of fattening
References
References
1. Montané, J.; Simon-Grifé, M.; Moros, A.; Puigvert, E.; González-González, L.; Pedernera, C.; Acal, L.; Sitjà, M.: Duration of immunity of a novel intradermal vaccine against Mycoplasma hyopneumoniae and PCV2 infection, ESPHM 2021, IMM-PP-25.
2. Montané, J.; Simon-Grifé, M.; Moros, A.; Puigvert, E.; González-González, L.; Pedernera, C.; Acal, L.; Sitjà, M.: Efficacy of a new intradermal vaccine against Mycoplasmahyopneumoniae and PCV2 infection. ESPHM 2021, IMMPP-29
3. Puig, A.; Perozo, E.; Sabaté, D.; Moros, A.; Roura, F.; March, R.; Montané, J.; Effect of Mhyosphere® PCV ID on the gowth performance under field conditions, ESPHM 2021, IMM-PP-20.

Nacho Bernal

Hipra

Ramon Jordà

Hipra
© 2000 - 2024 - Global Ag Media. All Rights Reserved | No part of this site may be reproduced without permission.